NAD+
Nicotinamide adenine dinucleotide, oxidized
NAD+ is the oxidized form of nicotinamide adenine dinucleotide, a nucleotide cofactor. It is not a peptide and does not have an amino-acid sequence.
Reviewed September 2026
- Residues
- Not a peptide. not applicable: Amino-acid residue count is not applicable to this non-peptide molecular structure.
- Average mass
- 663.4 Da. verified: Reference form: oxidized NAD+ reference structure, C21H27N7O14P2 (CID 5892); not NADH or an unspecified salt; formula C21H27N7O14P2. PubChem average molecular weight, not monoisotopic mass. Excludes unlisted counterions, solvent and formulation ingredients; not a sold-lot measurement.
- pI
- Not applicable. not applicable: A sequence-derived peptide pI is not applicable. Small-molecule ionization/pKa and solution pH are different properties; no small-molecule isoelectric model is asserted.
Reference details
| Residues | Not a peptide |
|---|---|
| Average mass | 663.4 Da |
| pI | Not applicable |
| Aliases | Nicotinamide adenine dinucleotide, oxidized |
|---|---|
| Research area | Metabolic |
| PubChem CID | 5892 |
Property basis and sources
These describe the reference compound or formulation, not identification or testing of the supplied lot.
Reference form: oxidized NAD+ reference structure, C21H27N7O14P2 (CID 5892); not NADH or an unspecified salt. Not a sold-lot identity or measurement.
- Residues: Not a peptide (not applicable). Amino-acid residue count is not applicable to this non-peptide molecular structure. Residues source 1
- Average mass: 663.4 Da (verified). Reference form: oxidized NAD+ reference structure, C21H27N7O14P2 (CID 5892); not NADH or an unspecified salt; formula C21H27N7O14P2. PubChem average molecular weight, not monoisotopic mass. Excludes unlisted counterions, solvent and formulation ingredients; not a sold-lot measurement. Average mass source 1
- pI: Not applicable (not applicable). A sequence-derived peptide pI is not applicable. Small-molecule ionization/pKa and solution pH are different properties; no small-molecule isoelectric model is asserted. pI source 1
Reference scope and linked records
Reference type: Non-peptide cofactor.
This is a research-reference entry, not a product certificate, treatment recommendation or administration guide. The sources below describe their own materials and methods. Catalogue identity, lot testing and clinical evidence are separate questions.
Catalogue context: NAD+. The product retains its own name and specification; this link does not certify equivalence to published study material.
Related references
Sources and their scope
- PubChem: NAD+, CID 5892. Source for the chemistry or study context discussed above; not an Aminos lot certificate.
- CD38 dictates age-related NAD decline and mitochondrial dysfunction. Source for the chemistry or study context discussed above; not an Aminos lot certificate.
Source check: 26 September 2026. This is an editorial source check, not a claim of independent clinical or laboratory review.
About NAD+
Identity and context
The plus sign belongs to the oxidized nicotinamide chemistry. NAD+ must be distinguished from reduced NADH and from precursors such as NMN or nicotinamide riboside. Those materials participate in related metabolism but are not interchangeable chemical identities.
Reference classification
Non-peptide cofactor. The linked catalogue product is NAD+. This reference does not independently authenticate the material supplied.
Storage and handling
Analytical specification
Confirm the oxidized form, stereochemical identity, counterions and water content. Use an assay that distinguishes NAD+ from related nucleotides and degradation products when the experiment depends on redox state.
Storage and experimental handling
Use the documented conditions for the actual chemical form and preparation. No universal storage temperature, expiry or solution shelf life is assigned here. Follow the lot documentation, safety data sheet and validated laboratory protocol; this page is not a reconstitution or administration guide.
Research evidence
| Area | Summary | Evidence |
|---|---|---|
| What the source examines | A primary study of CD38 investigated age-associated NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. It is evidence about NAD metabolism and a regulatory enzyme, not a trial showing that a supplied NAD+ preparation reverses ageing in people. | Source context |
| What cannot be inferred | Biological importance of an endogenous cofactor is not proof of benefit from administering it. A PubChem record identifies a reference structure; it does not certify the chemical form, purity or stability of an Aminos preparation. | Evidence limits |
References
Sources used for the data on this page, checked September 2026.
- PubChem: NAD+, CID 5892Primary source for the reference discussion; not lot-specific product evidence.
- CD38 dictates age-related NAD decline and mitochondrial dysfunctionPrimary source for the reference discussion; not lot-specific product evidence.
Reference information only. This page describes the chemistry and published research context of a laboratory compound. Nothing here is medical or dosing advice. Aminos compounds are for laboratory research use only and are not medicines.